Stock listing
NASDAQ:CSTL Castle Biosciences, Inc. Stock
Home listing (NASDAQ) of Castle Biosciences, Inc.
Follow Castle Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CSTL
$32.86 USD -0.52 (-1.6%)
Close on Nov 20, 2026
- Day range
- $32.57 – $33.38 USDNov 20, 2026
- Volume
- 309,216 sharesNov 20, 2026
- Market cap
- $1.01B USDAt the close on Nov 20, 2026 · price × 30.82M shares outstanding
- 52-week range
- $17.72 – $44.28 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $13.13M USDMedian day 357,666 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CSTL · Home | $32.86 USD | -0.52 (-1.6%) | 309,216 | $32.76 | $33.38 | $32.57 | $33.38 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CSTL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $32.86 | -0.52 | -1.6% | $32.76 | $33.38 | $32.57 | 309,216 | |
| $33.38 | +0.40 | +1.2% | $32.88 | $34.09 | $32.34 | 380,849 | |
| $32.98 | +0.23 | +0.7% | $33.35 | $34.24 | $32.51 | 339,179 | |
| $32.75 | -1.04 | -3.1% | $33.42 | $33.65 | $32.46 | 652,286 | |
| $33.79 | -0.71 | -2.1% | $34.50 | $34.50 | $32.57 | 347,752 | |
| $34.50 | +0.51 | +1.5% | $33.64 | $34.68 | $32.76 | 440,799 | |
| $33.99 | -0.43 | -1.2% | $34.71 | $36.00 | $33.84 | 335,269 | |
| $34.42 | +0.04 | +0.1% | $33.96 | $34.58 | $33.52 | 407,934 | |
| $34.38 | +1.86 | +5.7% | $32.85 | $34.46 | $32.41 | 563,375 | |
| $32.52 | -1.68 | -4.9% | $34.56 | $35.69 | $31.81 | 981,631 | |
| $34.20 | -1.55 | -4.3% | $35.17 | $35.71 | $33.65 | 701,872 | |
| $35.75 | +0.61 | +1.7% | $36.03 | $36.43 | $35.07 | 462,475 | |
| $35.14 | +0.20 | +0.6% | $35.32 | $36.00 | $34.83 | 455,612 | |
| $34.94 | -2.22 | -6.0% | $37.52 | $37.52 | $34.46 | 470,257 | |
| $37.16 | -1.35 | -3.5% | $38.03 | $38.43 | $36.73 | 334,258 | |
| $38.51 | +1.83 | +5.0% | $37.57 | $38.73 | $36.09 | 723,808 | |
| $36.68 | +2.17 | +6.3% | $34.51 | $37.38 | $34.51 | 431,159 | |
| $34.51 | +1.21 | +3.6% | $33.55 | $34.66 | $33.19 | 295,208 | |
| $33.30 | +0.22 | +0.7% | $33.20 | $33.79 | $32.84 | 235,840 | |
| $33.08 | -0.11 | -0.3% | $33.41 | $33.62 | $32.69 | 202,877 | |
| $33.19 | -1.18 | -3.4% | $34.13 | $34.55 | $33.06 | 335,419 | |
| $34.37 | +1.22 | +3.7% | $33.15 | $34.72 | $32.93 | 336,592 | |
| $33.15 | +0.985 | +3.1% | $32.65 | $33.55 | $32.09 | 272,493 | |
| $32.17 | +0.205 | +0.6% | $32.44 | $32.74 | $31.67 | 347,233 | |
| $31.96 | -1.84 | -5.4% | $33.82 | $34.15 | $31.80 | 381,900 | |
| $33.80 | +0.69 | +2.1% | $33.13 | $34.06 | $32.48 | 381,900 | |
| $33.11 | +0.23 | +0.7% | $32.47 | $33.77 | $32.47 | 243,200 | |
| $32.88 | +0.12 | +0.4% | $32.79 | $33.35 | $32.23 | 241,700 | |
| $32.76 | -1.66 | -4.8% | $34.42 | $34.42 | $32.31 | 239,000 | |
| $34.42 | +0.71 | +2.1% | $33.52 | $34.52 | $33.39 | 249,100 | |
| $33.71 | +0.71 | +2.2% | $32.54 | $33.76 | $32.25 | 373,800 | |
| $33.00 | -0.36 | -1.1% | $33.15 | $33.72 | $32.77 | 351,500 | |
| $33.36 | -3.29 | -9.0% | $36.65 | $37.99 | $33.10 | 609,100 | |
| $36.65 | +1.09 | +3.1% | $35.45 | $36.76 | $35.10 | 377,200 | |
| $35.56 | +0.305 | +0.9% | $35.56 | $35.92 | $34.75 | 167,700 | |
| $35.26 | -0.275 | -0.8% | $36.10 | $36.99 | $35.17 | 522,300 | |
| $35.53 | +0.65 | +1.9% | $34.90 | $36.03 | $34.14 | 639,600 | |
| $34.88 | -1.05 | -2.9% | $35.72 | $36.24 | $34.24 | 318,600 | |
| $35.93 | +0.12 | +0.3% | $35.81 | $36.27 | $35.09 | 228,400 | |
| $35.81 | +0.62 | +1.8% | $35.19 | $36.12 | $34.44 | 437,700 | |
| $35.19 | +0.31 | +0.9% | $34.88 | $35.84 | $33.90 | 439,200 | |
| $34.88 | +0.03 | +0.1% | $34.74 | $34.97 | $33.99 | 348,300 | |
| $34.85 | -0.14 | -0.4% | $35.53 | $35.53 | $34.57 | 431,000 | |
| $34.99 | -0.35 | -1.0% | $35.68 | $35.68 | $34.48 | 391,700 | |
| $35.34 | -1.44 | -3.9% | $36.54 | $36.54 | $35.29 | 530,200 | |
| $36.78 | +1.30 | +3.7% | $35.98 | $36.85 | $34.94 | 364,600 | |
| $35.48 | -0.02 | -0.1% | $35.50 | $36.82 | $35.26 | 559,300 | |
| $35.50 | +2.06 | +6.2% | $33.64 | $35.69 | $33.64 | 519,800 | |
| $33.44 | +1.11 | +3.4% | $32.30 | $33.53 | $32.16 | 165,400 | |
| $32.33 | +0.01 | 0.0% | $32.77 | $32.94 | $31.71 | 224,200 | |
| $32.32 | +0.01 | 0.0% | $31.97 | $32.70 | $31.44 | 237,800 | |
| $32.31 | -0.45 | -1.4% | $32.43 | $33.03 | $32.00 | 194,600 | |
| $32.76 | -0.15 | -0.5% | $32.57 | $33.58 | $32.28 | 217,000 | |
| $32.91 | +0.26 | +0.8% | $32.32 | $33.21 | $31.99 | 187,700 | |
| $32.65 | -0.77 | -2.3% | $33.50 | $34.00 | $32.38 | 268,000 | |
| $33.42 | -0.02 | -0.1% | $33.36 | $34.73 | $32.69 | 200,300 | |
| $33.44 | +0.41 | +1.2% | $33.00 | $34.09 | $32.89 | 396,200 | |
| $33.03 | -0.47 | -1.4% | $33.03 | $33.30 | $32.36 | 258,000 | |
| $33.50 | -0.76 | -2.2% | $34.02 | $34.28 | $32.80 | 372,600 | |
| $34.26 | +0.18 | +0.5% | $34.01 | $34.89 | $33.98 | 251,200 | |
| $34.08 | -0.92 | -2.6% | $34.80 | $34.84 | $33.62 | 456,300 | |
| $35.00 | +1.53 | +4.6% | $33.47 | $35.20 | $33.29 | 483,371 | |
| $33.47 | -0.73 | -2.1% | $33.65 | $34.54 | $31.70 | 357,666 | |
| $34.20 | +1.27 | +3.9% | $32.85 | $34.70 | $32.14 | 573,500 | |
| $32.93 | +0.61 | +1.9% | $32.41 | $34.01 | $32.41 | 322,900 |
- Ticker
- NASDAQ:CSTL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
Latest earnings call · Nov 5, 2026
Castle Biosciences (NASDAQ:CSTL) Q3 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Q3 2026 Earnings Presentation
Earnings · 32 slides
Latest news
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
Nov 12, 2026
Closed $34.50 (+1.5%) on Nov 12, 2026
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference
Nov 11, 2026
Closed $34.50 (+1.5%) on Nov 12, 2026
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
Nov 11, 2026
Closed $33.99 (-1.2%) on Nov 11, 2026
Castle Biosciences Reports Third Quarter 2026 Results
Nov 5, 2026
Closed $32.52 (-4.9%) on Nov 6, 2026
Castle Biosciences to Participate in Upcoming Investor Conferences
Oct 28, 2026
Closed $36.68 (+6.3%) on Oct 28, 2026
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
Oct 15, 2026
Closed $33.80 (+2.1%) on Oct 15, 2026
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
Oct 12, 2026
Closed $32.88 (+0.4%) on Oct 13, 2026
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
Sep 30, 2026
Closed $35.26 (-0.8%) on Oct 1, 2026
Castle Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 45 in the last 12 months · 316 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 30 calls with a replay · 30 with a transcript · latest Nov 5, 2026
- Decks
- 58 decks · latest November 2026
Where Castle Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CSTL · Home listing · This page | NASDAQ | United States | USD |
| Frankfurt:086 | Frankfurt | Germany | EUR |
| BOATS:CSTL | BOATS | United States | USD |
| Tradegate:086 | Tradegate | Germany | EUR |
Valuation
EV/sales 2.0× against a median of 4.4×: the lowest of 10 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $745.1M USD
- P/E
- Loss
- EV/sales
- 2.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.1×
- Gross margin
- 77.1%
- Operating margin
- −7.4%
- Net margin
- −6.1%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.00
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Castle Biosciences, Inc. · NASDAQ:CSTL | US$1.01B | US$745.1M | n/a | 2.0× | n/a | 2.1× | −6.1% | 0.0× | 1.00 |
| Vcanbio Cell & Gene Engineering Corp., Ltd. Class A · SSE:600645 | US$1.06B | US$786.1M | 62.8× | 3.8× | n/a | 1.9× | 8.2% | 0.0× | n/a |
| Beijing Strong Biotechnologies Inc Class A · SZSE:300406 | US$1.05B | US$1.13B | 28.0× | 5.5× | n/a | 1.9× | 18.2% | 0.3× | n/a |
| Freenome, Inc. · NASDAQ:FRNM | US$1.04B | US$863.3M | 9.5× | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Maravai LifeSciences Holdings, Inc. · NASDAQ:MRVI | US$1.04B | US$1.11B | n/a | 5.2× | n/a | 5.3× | −30.8% | 0.8× | 1.56 |
| Suzhou Novoprotein Scientific Co., Ltd. Class A · SSE:688137 | US$1.02B | US$909.1M | n/a | 38.0× | n/a | 3.4× | −60.8% | 0.0× | n/a |
| Guangzhou Wondfo Biotech Co., Ltd. Class A · SZSE:300482 | US$1.01B | US$785.0M | n/a | 2.7× | n/a | 1.2× | −3.2% | 0.0× | n/a |
| St Pharm Co., Ltd. · KRX:237690 | US$992.8M | US$866.1M | 17.4× | 3.0× | 11.1× | 2.1× | 19.9% | 0.0× | n/a |
| Daan Gene Co., Ltd. Class A · SZSE:002030 | US$990.1M | US$810.9M | n/a | 7.0× | n/a | 0.9× | −95.7% | 0.0× | n/a |
| Amoy Diagnostics Co., Ltd. Class A · SZSE:300685 | US$967.3M | US$801.3M | 18.8× | 4.4× | n/a | 3.3× | 28.5% | 0.1× | n/a |
| Novogene Co., Ltd. Class A · SSE:688315 | US$949.6M | US$685.6M | 43.1× | 2.0× | n/a | 2.3× | 6.4% | 0.0× | n/a |
| Median of the others | US$1.01B | US$837.1M | 23.4× | 4.4× | 11.1× | 2.1× | 6.4% | 0.0× | 1.56 |
Forecasts
9 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 48.20 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.82 · 9 analysts
- Revenue, year to Dec 2026
- 392.4M · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Derek J. Maetzold | Founder, President and CEO |
| Frank Stokes | Chief Financial Officer |
| Kristen Oelschlager | Chief Operating Officer |
| Camilla Zuckero | Vice President, Investor Relations & Corporate Affairs |
| Alice Izzo | Vice President, Regulatory and Government Affairs |
| Chris Otte | Vice President, Information Technology |
| Clare Johnson | Senior Vice President, Clinical Research |
| Darshini Weeratunga | Vice President, Accounting and SEC Reporting |
| Jay Braxton | Senior Vice President, Marketing |
| John Abbott | Vice President, Finance |
| Keli Greenberg | Vice President, Human Resources |
| Kevin Doman | Senior Vice President, Sales |
| Matthew Goldberg | Senior Vice President, Medical |
| Noreen Manning | Vice President, Reimbursement |
| Rebecca Critchley-Thorne | Vice President, Research & Development |
| Reeny Hedgemond | Vice President, Dermatology Marketing |
| Sherri Borman | Senior Vice President, Laboratory Director |
| Trisha Poteet | Senior Vice President, Clinical Services and Manufacturing Operations |
| Hillary Caruso | Chief of Staff |
| Janet Koch | Executive Director, Training, Events & Marketing Operations |
| Jennifer Saam | Executive Director, Medical Affairs |
| John Cheneval | Executive Director, Business Development |
| Michael Maltby | Executive Director, Managed Care |
| Peter Manetakis | Executive Director, Sales Operations |
| Toby Juvenal | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Daniel M. Bradbury | Board Chairman |
| Derek J. Maetzold | Founder, President and CEO |
| Ellen Goldberg | Director |
| G. Bradley Cole | Director |
| Janet Koch | Executive Director, Training, Events & Marketing Operations |
| Jennifer Saam | Executive Director, Medical Affairs |
| John Cheneval | Executive Director, Business Development |
| Kimberlee Caple | Director |
| Michael Maltby | Executive Director, Managed Care |
| Miles Harrison | Director |
| Peter Manetakis | Executive Director, Sales Operations |
| Rodney Cotton | Director |
| Tiffany Olson | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Castle Biosciences (NASDAQ:CSTL) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| Castle Biosciences (NASDAQ:CSTL) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 4:30 PM ET | Replay |
| Castle Biosciences (NASDAQ:CSTL) Q1 2026 Earnings Call | Wed, May 06, 2026 · 4:30 PM ET | Replay |
| Castle Biosciences (NASDAQ:CSTL) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 4:30 PM ET | Replay |
| Castle Biosciences (NASDAQ:CSTL) Q3 2025 Earnings Call | Mon, Nov 03, 2025 · 4:30 PM ET | Replay |
| Castle Biosciences (NASDAQ:CSTL) Q2 2025 Earnings Call | Mon, Aug 04, 2025 · 4:30 PM ET | Replay |
| Castle Biosciences (NASDAQ:CSTL) Q1 2025 Earnings Call | Mon, May 05, 2025 · 4:30 PM ET | Replay |
| Castle Biosciences (NASDAQ:CSTL) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 4:30 PM ET | Replay |
| Castle Biosciences (NASDAQ:CSTL) Q3 2024 Earnings Call | Mon, Nov 04, 2024 · 4:30 PM ET | Replay |
| Castle Biosciences (NASDAQ:CSTL) Q2 2024 Earnings Call | Mon, Aug 05, 2024 · 4:30 PM ET | Replay |
All 30 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −4.9% |
| Q2 2026 | Jul 30, 2026 · After close | +4.5% |
| Q1 2026 | May 6, 2026 · After close | −22.3% |
| Q4 2025 | Feb 26, 2026 | −4.1% |
| Q3 2025 | Nov 3, 2025 · After close | +21.7% |
| Q2 2025 | Aug 4, 2025 · After close | +32.8% |
| Q1 2025 | May 5, 2025 · After close | −11.4% |
| Q4 2024 | Feb 26, 2025 · Before open | +3.8% |
| Q3 2024 | Nov 4, 2024 · After close | −7.4% |
| Q2 2024 | Aug 5, 2024 · After close | +14.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | +6.5% |
| Q4 2023 | Feb 28, 2024 · After close | −25.9% |
| Q3 2023 | Nov 2, 2023 · After close | +8.0% |
| Q2 2023 | Aug 2, 2023 · After close | +11.8% |
| Q1 2023 | May 3, 2023 · After close | −3.9% |
| Q4 2022 | Feb 28, 2023 · After close | −9.2% |
| Q3 2022 | Nov 2, 2022 · After close | −2.0% |
| Q2 2022 | Aug 8, 2022 · After close | +7.6% |
| Q1 2022 | May 9, 2022 · After close | +5.8% |
| Q4 2021 | Feb 28, 2022 · After close | +7.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 32 slides | November 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 30, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 33 slides | May 6, 2026 |
| Technical Presentation (March 2026) | Technical | 29 slides | Mar 23, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 32 slides | Feb 26, 2026 |
| FY2025 Earnings Presentation | Earnings | 7 slides | January 2026 |
| Fact Sheet (November 2025) | Fact sheet | 2 slides | Nov 3, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 34 slides | November 2025 |
| Fact Sheet (August 2025) | Fact sheet | 2 slides | Aug 4, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 35 slides | August 2025 |
Show 50 decks
This page holds 50 of 58 decks. Open Decks
IPO
Priced at US$16.00 a share on Jul 24, 2019.
- Price
- US$16.00 a share
- Shares offered
- 4,000,000 shares of common stock
- Offering size
- US$64 million
- Underwriters
- SVB Leerink, Baird, Canaccord Genuity, BTIG · In the order on the cover
- Shares delivered
- On or about Jul 29, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 14, 2019 |
| Filed publicly | Jun 26, 2019 |
| Amended twice | Newest Jul 19, 2019 |
| Shares registered with an exchange | Jul 15, 2019 |
| Declared effective by the SEC | Jul 24, 2019 |
| Final prospectus, with the price | Jul 26, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 26, 2019 |
| EFFECT · Notice that a registration is effective | Jul 24, 2019 |
| S-1MEF · Registration of more shares for the same offering | Jul 24, 2019 |
| CORRESP · Letter to the SEC | Jul 23, 2019 |
| CORRESP · Letter to the SEC | Jul 23, 2019 |
| CERT · Exchange's certificate of listing | Jul 23, 2019 |
| FWP · Free writing prospectus | Jul 19, 2019 |
| S-1/A · Registration statement, amended | Jul 19, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 15, 2019 |
| CORRESP · Letter to the SEC | Jul 15, 2019 |
All 18 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jul 15, 2019 |
| S-1/A · Registration statement, amended | Jul 15, 2019 |
| CORRESP · Letter to the SEC | Jul 9, 2019 |
| UPLOAD · Letter from the SEC | Jul 8, 2019 |
| CORRESP · Letter to the SEC | Jun 26, 2019 |
| S-1 · Registration statement | Jun 26, 2019 |
| UPLOAD · Letter from the SEC | Jun 10, 2019 |
| DRS · Draft registration statement | May 14, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 26, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 344.2M | 332.1M | 219.8M | 137.0M | 94.1M | 62.6M | 51.9M | 22.8M | 13.8M |
| Cost of revenue | 71.0M | 60.2M | 45.0M | 32.0M | 15.8M | 9.69M | 7.31M | 5.30M | 4.92M |
| Gross profit | 273.2M | 271.9M | 174.8M | 105.0M | 78.3M | 53.0M | 44.6M | 17.5M | 8.83M |
| Research and development | 51.9M | 52.0M | 53.6M | 44.9M | 29.6M | 13.3M | 7.38M | 4.85M | 4.47M |
| Selling, general and administrative | 229.3M | 200.0M | 180.2M | 143.0M | 86.7M | 48.1M | 29.8M | 16.5M | 15.3M |
| Operating income | -42.8M | 8.67M | -68.0M | -72.9M | -40.1M | -6.54M | 7.33M | -3.84M | -10.9M |
| Depreciation and amortization | 40.8M | 16.0M | 12.3M | 10.5M | 3.41M | 472.0K | 354.0K | 287.0K | 310.8K |
| EBITDA | -2.04M | 24.7M | -55.6M | -62.3M | -36.7M | -6.07M | 7.68M | -3.55M | -10.6M |
| Interest expense | 86.0K | 577.0K | 11.0K | 17.0K | 1.00K | 2.63M | 4.57M | 2.27M | 1.65M |
| Income before tax | -29.5M | 21.6M | -57.4M | -68.9M | -40.0M | -10.2M | 5.35M | -6.36M | -12.4M |
| Income tax | -5.36M | 3.32M | 101.0K | -1.77M | -8.72M | 84.0K | 72.0K | 9.00K | 9.73K |
| Net income | -24.2M | 18.2M | -57.5M | -67.1M | -31.3M | -10.3M | 5.28M | -6.37M | -12.4M |
| Earnings per share, basic | -0.83 | 0.66 | -2.14 | -2.58 | -1.24 | -0.54 | 0.35 | -5.33 | -1.26 |
| Earnings per share, diluted | -0.83 | 0.62 | -2.14 | -2.58 | -1.24 | -0.54 | -0.21 | -5.33 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 116.7M | 119.7M | 98.8M | 122.9M | 329.6M | 409.9M | 98.8M | 4.48M | 1.21M |
| Short-term investments | 182.8M | 173.4M | 144.3M | 135.7M | 0 | 0 | 0 | ||
| Receivables | 43.4M | 51.2M | 38.3M | 23.5M | 17.3M | 12.8M | 14.6M | 12.1M | 4.65M |
| Inventory | 10.3M | 8.13M | 7.94M | 3.98M | 2.02M | 2.22M | 1.24M | 882.0K | 304.6K |
| Current assets | 361.1M | 360.2M | 295.6M | 292.3M | 353.7M | 429.6M | 116.7M | 18.1M | 6.68M |
| Property, plant and equipment | 14.3M | 9.50M | 7.10M | 2.06M | 1.53M | 1.47M | |||
| Goodwill | 10.7M | 10.7M | 10.7M | 10.7M | 0 | 0 | 0 | ||
| Total assets | 578.6M | 531.2M | 453.3M | 447.3M | 462.6M | 439.3M | 119.7M | 22.4M | 9.82M |
| Accounts payable | 18.7M | 6.90M | 10.3M | 4.73M | 2.55M | 2.10M | 1.86M | 1.45M | 1.12M |
| Current liabilities | 68.7M | 49.4M | 47.7M | 36.1M | 24.9M | 20.9M | 15.3M | 6.74M | 5.22M |
| Long-term debt | 9.64M | 9.74M | 0 | 0 | 19.3M | 24.5M | 17.6M | ||
| Total debt | 10.1M | 10.0M | 0 | 13.4M | 8.20M | 0 | 26.7M | 24.5M | 18.6M |
| Total liabilities | 107.7M | 75.4M | 62.1M | 48.2M | 50.8M | 23.6M | 34.6M | 32.5M | 24.1M |
| Shareholders' equity | 470.9M | 455.8M | 391.3M | 399.1M | 411.7M | 415.7M | 85.1M | -56.6M | -14.3M |
| Shares outstanding | 29.7M | 28.5M | 27.4M | 26.6M | 25.4M | 24.8M | 17.1M | 1.92M | 9.78M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 64.3M | 64.9M | -5.63M | -41.7M | -19.0M | 9.87M | 7.01M | -12.3M | -12.2M |
| Capital spending | -36.0M | -28.3M | -13.6M | -5.63M | -3.48M | -4.75M | -937.0K | -277.0K | -494.9K |
| Free cash flow | 28.3M | 36.5M | -19.2M | -47.3M | -22.5M | 5.11M | 6.08M | -12.6M | -12.7M |
| Cash from investing | -60.4M | -50.1M | -16.2M | -166.5M | -66.7M | -4.75M | -937.0K | -277.0K | -494.9K |
| Cash from financing | -6.96M | 6.14M | -2.30M | 1.51M | 5.42M | 305.9M | 88.3M | 15.8M | 8.87M |
| Dividends paid | -1.69M | -3.12M | 0 | 0 | |||||
| Share buybacks | -5.13M | -1.69M | -781.0K | 67.2M | 10.4M | 292.7K | |||
| Change in cash | -2.98M | 20.9M | -24.1M | -206.7M | -80.2M | 311.0M | 94.4M | 3.27M | -3.86M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Aug 14, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Aug 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 31, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 8-K · Current report | May 29, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 8, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 8, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 8, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 26, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Nov 3, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 23, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 9, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 13, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 8, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 8-K · Current report | May 23, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 23, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 9, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 9, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 9, 2025 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 8, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Mar 28, 2025 | Meeting notice | SEC |
This page holds 200 of 896 filings. Open Filings
Cap table
Built by 6ix from Castle Biosciences, Inc.’s releases · as of Oct 29, 2026
- Common shares
- 30,818,291
- Fully diluted
- 30,818,291
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 30,818,291 | Oct 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 29, 2026 | 30,818,291 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Daniel Bradbury Other companies: Vivani Medical, Inc. (Member of the Board · Since at least Mar 4, 2024); Equillium, Inc. (Chairman of the Board · Since at least Oct 11, 2018); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Intercept Pharmaceuticals Inc (Director · Jul 19, 2016 – Nov 8, 2023 · Past); BioMed Realty Trust (Director · Jan 1, 2013 – Jan 27, 2016 · Past); Corcept Therapeutics Incorporated (Director · Oct 10, 2012 – Feb 7, 2019 · Past); Geron Corporation (Director · Sep 26, 2012 – Mar 29, 2019 · Past); Illumina, Inc. (Director · Jun 8, 2006 – May 25, 2017 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2006 – Feb 13, 2008 · Past); Amylin Pharmaceuticals LLC (President & Chief Executive Of, Director · Jan 5, 2006 – Feb 22, 2012 · Past) | Board Chairman · Since at least Jul 24, 2019 |
| David Kabakoff Other companies: NextCure, Inc. (Director · Since at least May 8, 2019); Trius Therapeutics Inc (Director · Aug 2, 2010 – Sep 11, 2013 · Past); Avalon Pharmaceuticals Inc (Director · Oct 11, 2006 – Jun 4, 2008 · Past); InterMune Inc (Director · May 25, 2006 – Sep 29, 2014 · Past) | Director · Jul 24, 2019 – Jun 17, 2021 · Past |
| G. Bradley Cole Other companies: Kiniksa Pharmaceuticals International, plc (Director · Since at least Jul 27, 2020); EXACT Sciences Corporation (General Manager - Diagnostics · Nov 11, 2019 – Feb 19, 2020 · Past); Genomic Health Inc (CFO · Oct 6, 2011 – Nov 8, 2019 · Past) | Director · Since at least Jul 24, 2019 |
| Mara G Aspinall Other companies: Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 27, 2021 · Past); OraSure Technologies, Inc. (Director · Jun 21, 2017 – May 13, 2025 · Past); Safeguard Scientifics, Inc. (Director · Oct 23, 2014 – May 31, 2016 · Past) | Director · Jul 24, 2019 – May 23, 2024 · Past |
| Bonnie H Anderson Other companies: Bruker Corporation (Director · Since at least Sep 3, 2020); Veracyte, Inc. (Director · Oct 29, 2013 – Jun 2, 2023 · Past) | Director · Jul 24, 2019 – Jul 17, 2020 · Past |
| Derek Maetzold Other companies: Encysive Pharmaceuticals Inc (V.P., Marketing & Sales · Mar 2, 2006 – Apr 1, 2008 · Past) | Founder, President and CEO · Since at least Jul 24, 2019 |
| Frank Stokes Other companies: Exagen Inc. (Director · Since at least Jun 17, 2021) | Chief Financial Officer · Since at least Jul 24, 2019 |
| Frank Stokes Other companies: Exagen Inc. (Board Member · Since at least Nov 4, 2026) | Chief Financial Officer · Since at least Aug 17, 2026 |
| Tiffany Olson Other companies: MiMedx Group, Inc (Director · Since at least Mar 1, 2024) | Director · Since at least May 8, 2021 |
| Alice Izzo | Vice President, Regulatory and Government Affairs · Since at least Nov 5, 2026 |
All 41 people
| Person | Seat |
|---|---|
| Bernhard E Spiess | Chief Business Officer · Jul 24, 2019 – Sep 2, 2021 · Past |
| Camilla Zuckero | Vice President, Investor Relations & Corporate Affairs · Since at least Oct 28, 2026 |
| Chris Otte | Vice President, Information Technology · Since at least Nov 4, 2026 |
| Clare Johnson | Senior Vice President, Clinical Research · Since at least Nov 5, 2026 |
| Darshini Weeratunga | Vice President, Accounting and SEC Reporting · Since at least Nov 5, 2026 |
| Ellen Goldberg | Director · Since at least Jul 14, 2021 |
| Federico A Monzon | Chief Medical Officer · Jul 24, 2019 – May 22, 2020 · Past |
| Hillary Caruso | Chief of Staff · Since at least Nov 5, 2026 |
| Janet Koch | Executive Director, Training, Events & Marketing Operations · Since at least Nov 5, 2026 |
| Jay Braxton | Senior Vice President, Marketing · Since at least Nov 5, 2026 |
| Jennifer Saam | Executive Director, Medical Affairs · Since at least Nov 5, 2026 |
| John Abbott | Vice President, Finance · Since at least Nov 5, 2026 |
| John Cheneval | Executive Director, Business Development · Since at least Nov 5, 2026 |
| Joseph C Cook III | Director · Jul 24, 2019 – Mar 18, 2021 · Past |
| Keli Greenberg | Vice President, Human Resources · Since at least Nov 5, 2026 |
| Kevin Doman | Senior Vice President, Sales · Since at least Nov 5, 2026 |
| Kimberlee Caple | Director · Since at least May 27, 2026 |
| Kim Caple | Director · Since at least Jul 14, 2021 |
| Kristen Oelschlager | Chief Operating Officer · Since at least Apr 6, 2021 |
| Matthew Goldberg | Senior Vice President, Medical · Since at least Jul 15, 2026 |
| Michael Maltby | Executive Director, Managed Care · Since at least Nov 5, 2026 |
| Miles Harrison | Director · Since at least Apr 1, 2020 |
| Noreen Manning | Vice President, Reimbursement · Since at least Nov 5, 2026 |
| Peter Manetakis | Executive Director, Sales Operations · Since at least Nov 5, 2026 |
| Rebecca Critchley-Thorne | Vice President, Research & Development · Since at least Sep 9, 2026 |
| Reeny Hedgemond | Vice President, Dermatology Marketing · Since at least Nov 5, 2026 |
| Rodney Cotton | Director · Since at least Mar 26, 2024 |
| Sherri Borman | Senior Vice President, Laboratory Director · Since at least Nov 5, 2026 |
| Tobin W Juvenal | Chief Commercial Officer · Since at least Apr 6, 2021 |
| Toby Juvenal | Chief Commercial Officer · Since at least Jun 16, 2026 |
| Trisha Poteet | Senior Vice President, Clinical Services and Manufacturing Operations · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Castle Biosciences, Inc.